Short answer: better than in 2019, but not “ready.” The U.S. has made real progress on detection and medical countermeasures, yet still has big vulnerabilities in workforce, health‑care surge capacity, data sharing, supply chains, and public trust.
What’s stronger since COVID-19 (based on publicly released plans and evaluations through late 2024):
•Faster countermeasures: BARDA/ASPR and industry can move vaccines and treatments much faster than pre‑2020, with mRNA platforms, established clinical networks, and clearer Emergency Use Authorization playbooks.
•Federal coordination: HHS elevated its preparedness arm (ASPR); the White House stood up a pandemic preparedness office; CDC created dedicated forecasting and outbreak analytics and reorganized to speed response.
•Surveillance: Routine wastewater monitoring expanded nationwide; more electronic case/lab reporting; respiratory‑virus forecasting now exists to guide hospitals and the public.
•Stockpiles and manufacturing: The Strategic National Stockpile holds significantly more PPE and ventilatory support gear than in early 2020; the U.S. added more domestic capacity for masks, tests, and some vaccine components.
•Data modernization: Ongoing investments are pushing public‑health systems toward near‑real‑time feeds from labs, hospitals, and health departments.
Where the U.S. is still vulnerable:
•Public‑health workforce: Many state/local health departments lost experienced staff after the emergency; hiring pipelines and surge staffing remain thin.
•Health‑care surge: ICU, pediatric care, and long‑term‑care facilities lack sustained surge capacity; staffing, not just beds, is the bottleneck.
•Data gaps: Reporting laws, tech, and privacy rules vary by state; many facilities (especially long‑term care and outpatient settings) still don’t send timely, standardized data during crises.
•Supply chains: Persistent drug shortages (especially sterile injectables), reliance on a few overseas suppliers for active ingredients, and on‑again/off‑again domestic PPE/test production leave room for shocks.
•Trust and communication: High polarization and misinformation reduce uptake of vaccines/therapeutics and complicate non‑pharmaceutical measures.
•Funding stability: Much of the post‑COVID investment was one‑time; many capabilities (workforce, surveillance pilots, manufacturing “warm‑base” contracts) need steady funding to stay ready.
What “prepared” would look like:
•Stable, multi‑year funding for public health and hospital surge staffing.
•24–48 hour, nationwide situational awareness across hospitals, labs, long‑term care, and wastewater—using common data standards.
•Standby manufacturing contracts for vaccines, tests, PPE, and key drugs, with clear triggers to scale.
•Modernized buildings: routine ventilation/indoor‑air quality standards for schools, workplaces, and transit.
•Clear, pre‑agreed playbooks for risk communication and community measures, tailored by setting (schools, LTCFs, workplaces).
•Legal/benefit backstops that enable people to isolate or care for family (paid sick leave, free early‑wave testing and treatment).
Bottom line: As of today (October 31, 2026), the U.S. is more capable than it was before COVID‑19 in finding outbreaks early and delivering vaccines/therapeutics quickly, but key systems that determine how a crisis actually plays out—people, data, supply chains, and trust—are still not where they need to be. If you’d like, I can pull the latest 2025–2026 reports and legislation status (for example, stockpile readiness audits and PAHPA reauthorization updates) and tailor this to your state.